Table 1.

Table showing baseline patient characteristics of forty AML patients included in the study, stratified by low (<0.45) and high (≥0.45) composite IDO-1 score (The cut-off point of 0.45 was derived after a ROC analysis).

Patient characteristics (n  =  40)	Number of patients (%)	Composite IDO-1 score  <  0.45 (%)	Composite IDO-1 score ≥0.45 (%)	Median censored OS (in days)	P value
Age
<55	13 (32.5)	9 (69.2)	4 (30.8)	747	0.02*
56–74	19 (47.5)	5 (26.3)	14 (73.7)	284	0.6
>75	5 (12.5)	1 (20)	4 (80)	155	0.06
Sex
Male	16 (40)	3 (18.8)	13 (81.2)	217	0.02*
Female	24 (60)	12 (50)	12 (50)	553
Race
Caucasian	22 (55)	6 (27.3)	16 (72.7)	317	0.07
African- American	18 (45)	9 (50)	9 (50)	331
FAB subtype
M0	0 (0)	0 (0)	0 (0)	—	—
M1	6 (15)	1 (16.7)	5 (83.3)	340	0.5
M2	5 (12.5)	1 (20)	4 (80)	282	0.3
M3	1 (2.5)	1 (100)	0 (0)	—	0.08
M4	5 (12.5)	4 (80)	1 (20)	—	0.001*
M5	8 (20)	4 (50)	4 (50)	665	0.5
M6	2 (5)	0 (0)	2 (100)	151	0.17
M7	0 (0)	0 (0)	0 (0)	—	—
AML with myelodysplasia-related changes	11 (27.5)	2 (18.2)	9 (81.8)	207	0.005*
FAB subtype unknown	2 (5)	2 (100)	0 (0)	—	0.4
Risk category (based on cytogenetics/mutational analysis)
Good	4 (7.5)	3 (75)	1 (25)	—
Intermediate	27 (80)	12 (44.4)	15 (55.6)	377
Poor	9 (12.5)	0 (0)	9 (100)	147	0.002*
Allogeneic stem cell transplant
Yes	6 (15)	4 (66.7)	2 (33.3)	—	0.0005*
No	30 (75)	10 (33.3)	20 (66.7)	217
Unknown	4 (10)	1 (25)	3 (75)	711
Treatment
Standard induction ± maintenance	29 (72.5)	13 (44.8)	16 (55.2)	500	0.07
Hypomethylating agents	4 (10)	1 (25)	3 (75)	253
Untreated/unknown	7 (17.5)	1 (14.3)	6 (85.7)	207
Remission
Yes	20 (50)	13 (65)	7 (35)	756	<  0.0001*
No	19 (47.5)	1 (5.3)	18 (94.7)	147
Unknown	1 (2.5)	1 (100)	0 (0)	—
Relapse (If remission was achieved)
Yes	10 (25)	6 (60)	4 (40)	625	<0.0001*
No	10 (25)	7 (70)	3 (30)	—